National Centre for Immunisation Research and Surveillance (NCIRS), Kids Research Institute, The Children’s Hospital at Westmead, Locked Bag 4001, Westmead, NSW, 2145, Australia Jeannette L. Comeau, Jocelyn Chan & Kristine K. Macartney Discipline of Paediatrics and Child Health, University of Sydn...
(MMR) was introduced in England as a single-dose schedule at 12 to 13 months [10]. Before 1968, annual measles notifications in the UK ranged from 160,000 to 800,000, with biannual peaks [10]. Also, at that time, more than 90% of adults had serological or clinical evidence of ...
Another vaccine model based on epitope technology is in development at the Queensland Institute of Medical Research’s Berghofer Medical Research Institute (QIMR), which has partnered with BioPharmaceuticals Australia to fund this project [117]. The technology in development is a polyepitope-based chime...
In a phase 2 trial, the Sinopharm vaccine (BBIBP-CorV) was well tolerated and a 4 µg dose administered in a 2-dose schedule (days 0 and 21 or days 0 and 28) resulted in higher neutralising antibody titres than a 4 µg 2-dose schedule at days 0 and 14 or a single ...
(ECDC) recommendations, as well as experiences in other European countries and the need to be prepared for a future influenza pandemic, would support the inclusion of influenza vaccination in healthy children, specifically those under 5 years of age, in the routine Spanish vaccination schedule. ...
]. The primary immunisation schedule consists of two doses given at an interval of 2 weeks, with the earliest onset of protection following 7–10 days after completion [81]. Protective effectiveness against cholera was also evaluated during mass-vaccination campaigns in Vietnam and India [...
Q-Vax® is a phase I whole-cell vaccine, and its licensed use is limited to Australia, presumably due to the potential for a post-vaccination hypersensitivity response. Pre-clinical Q fever vaccine development is a major area of interest, and diverse approaches have been undertaken to develop...
The primary immunisation schedule consists of two doses given at an interval of 2 weeks, with the earliest onset of protection following 7–10 days after completion [81]. Protective effectiveness against cholera was also evaluated during mass-vaccination campaigns in Vietnam and India [55,80,82,...